{"title":"A Quality Improvement Project to Increase the Rate of HPV Vaccination Initiation in Adolescents","authors":"","doi":"10.33140/jcei/03/02/00004","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00004","url":null,"abstract":"The vaccination rate of the human papilloma virus vaccine [9vHPV] is low, with only 63% of eligible females and 50% eligible males receiving the vaccine in 2016. The aim of this quality improvement project was to increase the initiation rate of HPV vaccination at Smyrna Pediatrics by 20%, from 3.6% to 4.3% over four weeks. Two physicians, one nurse practitioner, and two medical assistants implemented this quality improvement initiative. There is a lack of education and standardized communication about HPV and 9vHPV to prevent against the virus. A standardized script was created so that all conversations between healthcare professionals and patients and their parents or guardians included the wording of the 9vHPV being recommended rather than optional. Educational material from the CDC was the standard handout given to each adolescent and their parent or guardian. Standardized education and communication was to be provided at each adolescent visit of the 125 eligible adolescents seen during the four-week implementation period, 4% (n = 5) agreed to receive the 9vHPV vaccine. With a baseline of 3.6% (n = 4), there was an 11.1% increase of initiation of 9vHPV. The use of standardized education documents presented to all patients and their parents or guardians established health education as the mainstay of the project and provided information about the importance of prevention and protection from the virus that the vaccine prevents. The implementation of results over a longer period of time may prove to be more effective for the practice’s increase of vaccination rates overall.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77094349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A New Monoclonal Antibody-Based Biosimilar GnRH Antagonist","authors":"Gregory M. Lee","doi":"10.33140/jcei.03.02.07","DOIUrl":"https://doi.org/10.33140/jcei.03.02.07","url":null,"abstract":"GHR106 is a monoclonal antibody generated against an oligopeptide corresponding to that in the extra cellular domains of human GnRH receptor. The humanized forms of GHR106 exhibit almost identical biological properties to those of decapeptide GnRH antagonists such as Antide and Cetrorelix. The Fc region of humanized GHR106 has been replaced with IgG4 subtype to eliminate activities of effector function. Therefore, the newly humanized GHR106-IgG4Fc can be used clinically as biosimilar GnRH antagonists of higher molecular size, and longer half-life (hrs. vs. days) for therapeutic treatments of fertility-related health conditions without complications arising from the effector functions of immunoglobulins.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79733852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Tlamçani, A. Krich, Fatima Zahrae El Hamdi, M. A. Hassani
{"title":"A Still Rare Case of Congenital Afibrinogenemia","authors":"I. Tlamçani, A. Krich, Fatima Zahrae El Hamdi, M. A. Hassani","doi":"10.33140/jcei/03/02/00002","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00002","url":null,"abstract":"Congenital afibrinogenemia is characterized by the decrease or the absence of fibrinogen synthesis. It is a rare pathology that is transmitted autosomal recessive mode, with variable clinical demonstrations. The biological diagnosis consists in the presence of traces or absence of fibrogen with blood incoagulability. The coverage of this disease bases itself on the preventive treatment and replacement therapy based on fresh frozen plasma or fibrinogen concentrate. Through this case, we recall the various aspects of these rare condition clinical, biological, genetical as well as therapeutic plans.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80177110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Protective Effect of Myrianthus Arboreus Leaves Aqueous Extract in AcetaminophenInduced Liver Toxicity in Rats","authors":"","doi":"10.33140/jcei/03/02/00001","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00001","url":null,"abstract":"Owning to changes in living pattern of humans and constant environmental changes, different life challenging diseases now exist. Traditional system has clam that some of these diseases could be cured with plant. Plants and their components are source of large amount of drugs. This study was design to examine the protective effect of Myrianthus arboreus leaves extract against acetaminophen induced liver toxicity in rats. A suspension of 750 mg/kg acetaminophen was administered once every 72 hours to induce toxicity in the rats. Oral administration of 500, 1000 and 2000 mg/kg body weight of the extract and 100 mg/kg of silymarine (reference drug) were administered for 10 days. The result of effect of pretreatment with Myrianthus aboreus leaves on the enzyme makers of tissue damage in acetaminophen induced toxicity showed significant different when compared with the result of group induced without pretreatment. The values of AST, ALT and ALP in the untreated group significantly (p<0.05) increased. Elevated serum level in these enzymes revealed the integrity and functionality of the liver. Thus the increased value of these enzymes indicates damage to the liver by the induced acetaminophen. Also the values of non-enzyme markers (T.B., ALB and TG) for the treated groups decreased when compared with the untreated group. The significant different in the values between the groups pretreated with Myrianthus aboreus leaves and the untreated group showed that MA extract could protect the liver.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89580653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epstein - Barr virus Reactivation Associated with an Increased Thymidine Kinase and Normalized by an Immuno Modulatory Nano-Therapy: Three Case Reports","authors":"","doi":"10.33140/jcei/03/01/00001","DOIUrl":"https://doi.org/10.33140/jcei/03/01/00001","url":null,"abstract":"Epstein-Barr Virus (EBV), a common human herpes virus known to infect most of the world population, has been mentioned in the context of many diverse human pathologies while its participation during its latency phase is more and more often demonstrated in a growing number of chronic malignancies.The biological diagnosis of the virus activity is carried out using serological parameters on the one hand, and the measurement of the viral load on the other hand. Thymidine kinase (TK) is a key enzyme in the regulation of the intranuclear thymidine pool during cell cycle progression. The rise in its plasma level therefore systematically reveals an uncontrolled cellular proliferation evoking, of course, at first a neoplastic process. Nevertheless, EBV being a DNA virus, its reactivation or even a persistent primary infection are also likely to cause an increase in the blood level of TK.Using three examples, we will show that the neutralization of EBV by an immunomodulatory nano-therapy called Bio Immune (G)ene Medicine (BI(G)MED), is accompanied by a normalization of plasma levels of TK, thus underlining the close link between the virus and this marker of cell proliferation.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91083766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Q&A on the Paper of Kurukulasuriya et al. (2017) on IBD Vaccine Efficacy Against\u0000a Canadian Variant IBDV Strain in Broiler Chickens","authors":"","doi":"10.33140/jcei/03/01/00003","DOIUrl":"https://doi.org/10.33140/jcei/03/01/00003","url":null,"abstract":"Kurukulasuriya, et al. (2017) are reporting the efficacy of two IBD vaccines against an early (6 days post-hatch) challenge\u0000with a variant Canadian IBDV strain in broilers. A modified live vaccine(UNIVAX BD) administered by SQ route at 1 dayof-age delayed infection whereas an HVT-IBD vector vaccine (VAXXITEK HVT+IBD) administered in ovodid not protect.\u0000Furthermore, the authors suggested that the HVT-IBD vector induced immunosuppression responsible for an earlier IBDV\u0000challenge strain replication in the bursa.\u0000The data presented in the paper showed no evidence of VAXXITEK HVT+IBD vaccine take since the mean IBD ELISA\u0000antibody titer at D35 in the vaccinated/non-challenged group was not significantly different from that of the non-vaccinated\u0000group. It wasmuch lower than the expected one based on previous studies performed in the same conditions : in ovo\u0000vaccination of broilers [1,2]. Since there is no evidence of vaccine take, the other potential effects (immunosuppression and\u0000earlier IBDV replication in the bursa) observed in that group cannot be attributed to the vaccine.\u0000Since its launch in 2006 in Brazil, VAXXITEK HVT+IBD has been licensed in more than 75 countries and more than 80\u0000billion birds have been vaccinated. VAXXITEK HVT+IBD is protecting against a wide variety of IBDV strains including\u0000the classical, the very virulent and different variant strains. To our knowledge, noabsence of efficacy nor bursa depletions\u0000have been so far officially reported as long as the vaccine has been administered properlyto healthy embryonated eggs or\u0000to healthy one-day-old chicks.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76634613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}